224 related articles for article (PubMed ID: 19307502)
1. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome.
Scotlandi K; Remondini D; Castellani G; Manara MC; Nardi F; Cantiani L; Francesconi M; Mercuri M; Caccuri AM; Serra M; Knuutila S; Picci P
J Clin Oncol; 2009 May; 27(13):2209-16. PubMed ID: 19307502
[TBL] [Abstract][Full Text] [Related]
2. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL
Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047
[TBL] [Abstract][Full Text] [Related]
3. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.
Pasello M; Michelacci F; Scionti I; Hattinger CM; Zuntini M; Caccuri AM; Scotlandi K; Picci P; Serra M
Cancer Res; 2008 Aug; 68(16):6661-8. PubMed ID: 18701490
[TBL] [Abstract][Full Text] [Related]
4. Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy.
Schaefer KL; Eisenacher M; Braun Y; Brachwitz K; Wai DH; Dirksen U; Lanvers-Kaminsky C; Juergens H; Herrero D; Stegmaier S; Koscielniak E; Eggert A; Nathrath M; Gosheger G; Schneider DT; Bury C; Diallo-Danebrock R; Ottaviano L; Gabbert HE; Poremba C
Eur J Cancer; 2008 Mar; 44(5):699-709. PubMed ID: 18294840
[TBL] [Abstract][Full Text] [Related]
5. Favorable outcome of Ewing sarcoma family tumors to multiagent intensive preoperative chemotherapy: a single institution experience.
Moschovi M; Trimis G; Stefanaki K; Anastasopoulos J; Syriopoulou V; Koultouki E; Tzortzatou-Stathopoulou F
J Surg Oncol; 2005 Mar; 89(4):239-43. PubMed ID: 15726621
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth.
Carrillo J; García-Aragoncillo E; Azorín D; Agra N; Sastre A; González-Mediero I; García-Miguel P; Pestaña A; Gallego S; Segura D; Alonso J
Clin Cancer Res; 2007 Apr; 13(8):2429-40. PubMed ID: 17438102
[TBL] [Abstract][Full Text] [Related]
7. Current treatment for Ewing's sarcoma.
Thacker MM; Temple HT; Scully SP
Expert Rev Anticancer Ther; 2005 Apr; 5(2):319-31. PubMed ID: 15877528
[TBL] [Abstract][Full Text] [Related]
8. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998.
Bacci G; Longhi A; Ferrari S; Mercuri M; Versari M; Bertoni F
Acta Oncol; 2006; 45(4):469-75. PubMed ID: 16760184
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma.
Pellizzari Tregno F; Sau A; Pezzola S; Geroni C; Lapenta C; Spada M; Filomeni G; Bonanno E; Federici G; Caccuri AM
Eur J Cancer; 2009 Sep; 45(14):2606-17. PubMed ID: 19665369
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of Ewing's sarcoma.
Iwamoto Y
Jpn J Clin Oncol; 2007 Feb; 37(2):79-89. PubMed ID: 17272319
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced caspase-3 activation in a Ewing tumor cell line and primary Ewing tumor cells.
Mauz-Körholz C; Kachel M; Harms-Schirra B; Klein-Vehne A; Tunn PU; Körholz D
Anticancer Res; 2004; 24(1):145-9. PubMed ID: 15015589
[TBL] [Abstract][Full Text] [Related]
13. Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.
Johansson K; Ito M; Schophuizen CM; Mathew Thengumtharayil S; Heuser VD; Zhang J; Shimoji M; Vahter M; Ang WH; Dyson PJ; Shibata A; Shuto S; Ito Y; Abe H; Morgenstern R
Mol Pharm; 2011 Oct; 8(5):1698-708. PubMed ID: 21851097
[TBL] [Abstract][Full Text] [Related]
14. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways.
de Hooge AS; Berghuis D; Santos SJ; Mooiman E; Romeo S; Kummer JA; Egeler RM; van Tol MJ; Melief CJ; Hogendoorn PC; Lankester AC
Clin Cancer Res; 2007 Jan; 13(1):206-14. PubMed ID: 17200356
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cell features of Ewing tumors.
Tirode F; Laud-Duval K; Prieur A; Delorme B; Charbord P; Delattre O
Cancer Cell; 2007 May; 11(5):421-9. PubMed ID: 17482132
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future.
Rodriguez-Galindo C; Spunt SL; Pappo AS
Med Pediatr Oncol; 2003 May; 40(5):276-87. PubMed ID: 12652615
[TBL] [Abstract][Full Text] [Related]
17. [Preoperative adjuvant therapy for primary malignant bone tumors].
Goto T; Okuma T; Nakada I; Hozumi T; Kondo T
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1750-4. PubMed ID: 18030009
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases.
Federici L; Lo Sterzo C; Pezzola S; Di Matteo A; Scaloni F; Federici G; Caccuri AM
Cancer Res; 2009 Oct; 69(20):8025-34. PubMed ID: 19808963
[TBL] [Abstract][Full Text] [Related]
19. [Ewing sarcoma].
Hamanoue S; Makimoto A
Gan To Kagaku Ryoho; 2007 Feb; 34(2):175-80. PubMed ID: 17301523
[TBL] [Abstract][Full Text] [Related]
20. Extraosseous localized ewing tumors: improved outcome with anthracyclines--the French society of pediatric oncology and international society of pediatric oncology.
Castex MP; Rubie H; Stevens MC; Escribano CC; de Gauzy JS; Gomez-Brouchet A; Rey A; Delattre O; Oberlin O
J Clin Oncol; 2007 Apr; 25(10):1176-82. PubMed ID: 17401006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
